These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18524891)

  • 1. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness.
    de la Iglesia N; Konopka G; Lim KL; Nutt CL; Bromberg JF; Frank DA; Mischel PS; Louis DN; Bonni A
    J Neurosci; 2008 Jun; 28(23):5870-8. PubMed ID: 18524891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and Transformation.
    Puram SV; Yeung CM; Jahani-Asl A; Lin C; de la Iglesia N; Konopka G; Jackson-Grusby L; Bonni A
    J Neurosci; 2012 Jun; 32(23):7806-18. PubMed ID: 22674257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.
    de la Iglesia N; Konopka G; Puram SV; Chan JA; Bachoo RM; You MJ; Levy DE; Depinho RA; Bonni A
    Genes Dev; 2008 Feb; 22(4):449-62. PubMed ID: 18258752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells.
    Senft C; Priester M; Polacin M; Schröder K; Seifert V; Kögel D; Weissenberger J
    J Neurooncol; 2011 Feb; 101(3):393-403. PubMed ID: 20589525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma.
    Chen Q; Weng HY; Tang XP; Lin Y; Yuan Y; Li Q; Tang Z; Wu HB; Yang S; Li Y; Zhao XL; Fu WJ; Niu Q; Feng H; Zhang X; Wang Y; Bian XW; Yao XH
    J Pathol; 2019 Feb; 247(2):266-278. PubMed ID: 30357833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line.
    Moon SH; Kim DK; Cha Y; Jeon I; Song J; Park KS
    Int J Oncol; 2013 Mar; 42(3):921-8. PubMed ID: 23314408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doubles game: Src-Stat3 versus p53-PTEN in cellular migration and invasion.
    Mukhopadhyay UK; Mooney P; Jia L; Eves R; Raptis L; Mak AS
    Mol Cell Biol; 2010 Nov; 30(21):4980-95. PubMed ID: 20733006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy.
    Huang X; Zhang Y; Tang Y; Butler N; Kim J; Guessous F; Schiff D; Mandell J; Abounader R
    Neoplasia; 2013 Aug; 15(8):952-65. PubMed ID: 23908595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN signaling pathways in glioblastoma.
    Koul D
    Cancer Biol Ther; 2008 Sep; 7(9):1321-5. PubMed ID: 18836294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential SKIP expression in PTEN-deficient glioblastoma regulates cellular proliferation and migration.
    Davies EM; Kong AM; Tan A; Gurung R; Sriratana A; Bukczynska PE; Ooms LM; McLean CA; Tiganis T; Mitchell CA
    Oncogene; 2015 Jul; 34(28):3711-27. PubMed ID: 25241900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.
    Li Y; Guessous F; DiPierro C; Zhang Y; Mudrick T; Fuller L; Johnson E; Marcinkiewicz L; Engelhardt M; Kefas B; Schiff D; Kim J; Abounader R
    Mol Cancer Ther; 2009 Feb; 8(2):376-85. PubMed ID: 19190120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3 regulation of glioblastoma pathogenesis.
    de la Iglesia N; Puram SV; Bonni A
    Curr Mol Med; 2009 Jun; 9(5):580-90. PubMed ID: 19601808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
    Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
    Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SH3GL3 acts as a novel tumor suppressor in glioblastoma tumorigenesis by inhibiting STAT3 signaling.
    Nie Z; Cai S; Wei Z; Li Y; Bian L; Wang C; Wang X; Wang C
    Biochem Biophys Res Commun; 2021 Mar; 544():73-80. PubMed ID: 33524871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype.
    Duan S; Yuan G; Liu X; Ren R; Li J; Zhang W; Wu J; Xu X; Fu L; Li Y; Yang J; Zhang W; Bai R; Yi F; Suzuki K; Gao H; Esteban CR; Zhang C; Izpisua Belmonte JC; Chen Z; Wang X; Jiang T; Qu J; Tang F; Liu GH
    Nat Commun; 2015 Dec; 6():10068. PubMed ID: 26632666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation.
    Park MJ; Kim MS; Park IC; Kang HS; Yoo H; Park SH; Rhee CH; Hong SI; Lee SH
    Cancer Res; 2002 Nov; 62(21):6318-22. PubMed ID: 12414663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets.
    Cenciarelli C; Marei HE; Zonfrillo M; Casalbore P; Felsani A; Giannetti S; Trevisi G; Althani A; Mangiola A
    Oncotarget; 2017 Mar; 8(11):17873-17886. PubMed ID: 28157712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
    Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
    PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies.
    Peixoto P; Blomme A; Costanza B; Ronca R; Rezzola S; Palacios AP; Schoysman L; Boutry S; Goffart N; Peulen O; Maris P; Di Valentin E; Hennequière V; Bianchi E; Henry A; Meunier P; Rogister B; Muller RN; Delvenne P; Bellahcène A; Castronovo V; Turtoi A
    Oncogene; 2016 Aug; 35(34):4481-94. PubMed ID: 26853466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.